Patients |
1 |
2 |
3 |
4 |
Group |
Mono Dual therapy |
Mono Dual therapy |
HAART |
Mono Dual therapy |
Sex |
M |
F |
F |
F |
Year of birth |
1996 |
1997 |
1998 |
2005 |
Maternal age (years) |
31.8 |
34.9 |
39 |
33.4 |
Maternal CD4 T-cells count (/ml) |
98 |
64 |
3%* |
540 |
Maternal viral load (c/ml) [log10] |
Unknown |
340.000
[5.53] |
880.000
[5.94] |
400
[2.6] |
Maternal treatment |
AZT |
AZT+3TC |
AZT+3TC+NFV |
AZT+3TC |
Maternal mode of contamination |
IVDU |
Sexual |
Sexual |
Sexual |
Mode of delivery |
Vaginal |
Vaginal |
Elective caesarean |
Elective caesarean |
Co-infection |
HCV |
No |
No |
No |
Children prophylaxis |
AZT |
AZT+3TC |
AZT+3TC |
AZT |
Birth term (weeks) |
42.9 |
40.1 |
39 |
38 |
Birth weight (g) |
3,300 |
3,700 |
1,900 |
3,270 |
*: no absolute count available
IVDU : intravenous drug user, AZT : azidothymidine, 3TC : lamivudine, NFV : nelfinavir |